2 ASX healthcare stocks that were glowing this week- Alcidion & Recce Pharma

Source: Guschenkova, Shutterstock


  • Alcidion has been chosen as the preferred provider for an important healthcare IT project as part of a Consortium.
  • The Company also notified that the project initiation is scheduled for the fourth quarter of CY2021.
  • Recce Pharmaceuticals revealed that its lead compound RECCE® 327 had been registered in the ANZCTR.

ASX-listed leading provider of software solutions Alcidion Group Limited (ASX:ALC) has updated the market that it was selected as the preferred provider for an enterprise Healthcare Knowledge Management System. The Company also announced the acquisition of ExtraMed and provided an update on strong organic growth.

Another, healthcare stock Recce Pharmaceuticals Ltd’s (ASX:RCE), also performed well this week following a key announcement related to the  registration of its lead compound RECCE 327.  

With the key updates this week, the two stocks generated decent returns with ALC up ~14% and RCE increasing by 10%.

Other ASX healthcare shared ending the week on a high include Mayne Pharma (ASX:MYX), up 10.869%, Incannex Healthcare Limited (ASX:IHL), up 8.510%, and Anatara Lifesciences Ltd (ASX:ANR), up 8.33%.

ALSO READ: Why are Mayne Pharma and Antara Lifesciences shares flying high today?

Let us now dive deep and discuss the announcements of ALC and RCE:

Alcidion selected as the preferred provider for a key healthcare IT project

On 15 April 2021, Alcidion disclosed that the Company had been selected as the preferred provider for major healthcare IT project as part of a Consortium. In this project, the Company will capture data and support clinical decision making across the Australian Defence Force.

As a preferred provider, the Company will offer the Longitudinal Health Record through its Miya Precision product, combining the data from Consortium partners and other systems in the Defence environment to support the HKM solution.

The Company also notified that the project initiation is scheduled for the fourth quarter of the calendar year 2021 and will be subject to final approvals from the government for the funding and solution.

Kate Quirke, the Managing Director and CEO of Alcidion, commented-

Acquisition of ExtraMed

Alcidion has acquired ExtraMed, a leading UK NHS provider with more than 20 years of track record specialising in providing patient flow management software that helps frontline staff make informed decisions based on real-time visibility of patient flow. With the acquisition, Alcidion will become the leader in the UK market for patient flow.

Source: Copyright © 2021 Kalkine Media Pty Ltd

Furthermore, this will improve the overall presence of Alcidion to 27 NHS Trusts, indicating a market share of ~19% of the NHS acute care market and providing additional touchpoints from which to cross-sell the broader product suite of Alcidion.

Strong March Quarter sales momentum

Source: Copyright © 2020 Kalkine Media Pty Ltd

Alcidion disclosed that in the third quarter of the FY21 strong sales momentum has continued with:

  • Alcidion Group contracted revenue (except fourth-quarter revenue from ExtraMed) of AU$24.7 million recognised in the financial year 2021.
  • The Company stated that almost AU$3.0 million revenue was added during the quarter, driven by several contract extensions in Australia, New Zealand, and the UK.
  • The full-year revenue for FY20 now surpasses AU$18.6 million by 33%.

ALSO READ: Two Australian healthcare penny stocks on watch today - UBI, AVE

Recce Pharma Registered RECCE® 327 in ANZCTR

On 15 April 2021, Recce Pharmaceuticals announced that its lead compound RECCE® 327 or R327 had been registered in the ANZCTR (Australian New Zealand Clinical Trial Registry) for its Phase 1/2 clinical trials for topical burns.

Source © Mazirama | Megapixl.com

The Australian New Zealand Clinical Trial Registry is an online registry for the clinical trials being performed in Australia, NZ and elsewhere. The ANZCTR incorporates clinical studies from the complete spectrum of therapeutic areas, including pharmaceuticals, preventive measures, lifestyle, devices, surgical procedures, treatment, and rehabilitation strategies, along with complementary therapies. The Company further revealed that this registration signifies one of the final administrative stages to initiate the clinical trials.

The Company’s clinical trial involves 30 patients for the assessment of the safety and efficacy of R327.

Furthermore, Recce Pharmaceuticals stated that ten patients would get R327 daily over 14 days while a further 20 get therapy three times a week. The Company was looking forward to updating the market on clinical trial’s progression in the future.

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK